Unrelated cord blood (UCB) is an alternate stem cell source for patients lacking matched family donors. Speed of availability, tolerance of HLA disparity, reduced acute GVHD and reduced risk of viral disease transmission are advantages of UCB over unrelated bone marrow. We report the results of all unrelated UCB transplants performed in Australasian paediatric HSCT centres over the last 10 years. Between April 1995 and July 2005, 136 patients were transplanted for malignant (n ϭ 101; 74%) and non-malignant (n ϭ 33) diseases. Log-rank tests and Cox regression analysis were used to determine the effects of demographic, graft-related and treatment factors on engraftment, GVHD, TRM and survival. Median follow-up for surviving patients is 19 months (range, 1-108). The median age and weight of recipients is 5.1 years (range, 0.2 to 18) and 19 kg (range, 7 to 101), respectively. Median infused total nucleated cell (TNC) dose was 4.6 ϫ 10 7 NC/kg (range, 0.7-49.9) and median infused CD34 cell dose was 1.9 ϫ 10 5 /kg (range, 0.1-33). 16% of patients received a 6/6 HLAmatched unit, 44% a 5/6, 39% a 4/6 and 1 patient received a 3/6 HLA-matched unit. The incidence of neutrophil recovery by day 42 was 0.82 (95% [CI], 0.75-0.89) with a median time of 23 days (range, 10-55) to achieve engraftment (defined as ANC Ն0.5 ϫ 10 9 /L). The incidence of platelet recovery by day 60 was 0.46 (CI, 0.37-0.55) with a median time of 47 days to achieve a platelet count Ն 20 ϫ 10 9 /L. Incidences of grades II-IV and III-IV acute GVHD were 0.41 (CI, 0.32-0.5) and 0.18 (95% CI, 0.10-0.26), respectively. TRM and survival at 1-year post transplant was 0.31 (CI, 0.23-0.39) and 0.62 (CI, 0.54-0.70), respectively. Leukaemic relapse at 2 years was 0.23 (CI, 0.12-0.34). In Cox regression analysis, time to engraftment was consistently the only factor identified to be of significance. Time to engraftment was significantly faster when the infused CD34 dose was Ͼ1.7 ϫ 10 5 /kg (P ϭ .001) (median 18 days (CI 16-20) vs. 26 days . A TNC dose Ͼ3.0 ϫ 10 7 /kg was associated with higher overall engraftment rates but had no significant impact on speed of engraftment (P ϭ .08). This large paediatric series confirms that unrelated UCB is a viable stem cell source and that higher CD34 cell doses results in a significantly faster time to engraftment.
BONE MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA
In this study we report the long-term results of bone marrow transplantation (BMT) in 113 patients (M 56, F 57) with thalassemia major (TM) who were given 117 transplants from HLA identical sibling donor between May 1983 and September 2005. The median age was 9.09 years (0.11-28.11 ). The median number of transfusions given before BMT was 136 (2-900). The pretransplant liver biopsy performed in 78 patients showed: chronic persistent hepatitis in 35, mild chronic active hepatitis (CAH) in 10, moderate CAH in 23, severe CAH in 10. All patients received the same preparative therapy consisting of busulphan (BU) (13-14 mg/kg) and cyclophosphamide (200 mg/kg), preceded by an hypertransfusion regimen for 2-3 weeks. For graft-versus-host disease (GvHD) prophylaxis, 38 patients were given cyclosporine (CSA) alone and 75 received CSA and short course methotrexate. The median number of transplanted nucleated cells was 4.8 ϫ 10 8 /kg (2.3-10.1). Marrow engraftment was evident in 111 patients. The median time to achieve 0.5 ϫ 10 9 /L neutrophils and 50 ϫ 10 9 /L platelets was 19 (11-37) and 24 (10-55) days respectively. Four patients had an autologous reconstitution and are currently alive under transfusion therapy. The probability of graft rejection was 6.6%. The actuarial probability of developing acute GvHD grade II-IV and cumulative chronic GvHD was 21% and 17% (7% limited, 10% extensive) respectively. Transplant related mortality was 8.8%. Ten patients died for BMT related causes: pneumonia in 4, heart failure in 3, encephalopathy in 2, aGvHD in 1. Two late deaths occurred, one for septic shock 54 months post-BMT and one for parotitis carcinoma 138 months after BMT. As of October 2005, 101 patients are alive and 97 of them are cured after a median follow-up of 158 months (1-269). The 10-year actuarial probability of survival and disease-free survival (DFS) was 91% and 87% respectively. In multivariate analysis, no adverse risk factor affecting survival and DFS was identified among recipient-donor age and sex, number of pre-BMT transfusions, level of ferritin, type of CAH, grade of liver fibrosis, serum GPT level, HBV and HCV serology, dose of BU, type of GvHD prophylaxis, marrow cell dose. This study confirms the feasibility of curing the majority of patients with TM by BMT. Leukocyte adhesion deficiency (LAD) is an immunodeficiency disease resulting from defects in the integrin CD18. Children with LAD suffer severe, recurrent bacterial infections due to failure of leukocytes to adhere to endothelium and migrate to sites of infection. Approximately 75% of severe LAD patients die by two years of age. Allogeneic hematopoietic stem cell transplant after myeloablation can cure LAD, however regimenrelated toxicity and graft-vs.-host disease (GvHD) limit the use of this approach. Genetic correction of autologous CD34ϩ cells represents an optimal therapy for LAD since no donor is required, nor is GvHD a risk. In this study we developed a retroviral vector that confers a selectable growth advantage for pre-clinical testing of gene therapy in the canine model of LAD (CLAD). This retroviral vector allows for correction of the CD18 defect in CLAD and selection of the corrected cells. The vector, MSCV(cCD18)IRES-cMGMT‫ء‬P144K, harbors the canine CD18 cDNA followed by an internal ribosome entry site (IRES) for expression of mutated canine methylguanine methyltransferase (MGMT). Mutant MGMT confers resistance to the combination of carmustine (BCNU) and O6-benzylguanine (BG). A high-titer producer line was identified using the PG13 packaging line, and supernatant from this producer line was used to transduce an EBV-transformed B cell line derived from a CD18-LAD patient. Transduced and mock-transduced cells were grown in 25 M BG and increasing concentrations of BCNU. In one experiment, 5 M BCNU ϩ 25 M BG allowed selection of CD18ϩ cells to Ͼ 99% purity, however a distinct CD18-population remained. In a second experiment, cells selected in 10 M BCNU ϩ 25 M BG were ϳ 99.9% CD18ϩ with no distinct CD18Ϫ population. These studies demonstrate that a bicistronic retroviral vector leads to selection of a population of molecularly corrected LAD cells. Selection was achieved despite placement of MGMT after the IRES, where expression of the selectable gene product is expected to be decreased. Experiments with CD34ϩ cells from CLAD dogs will allow this approach to be tested in vivo. These studies Oral Presentations demonstrate that mutant MGMT after an IRES facilitates the selection of cells expressing a gene that is therapeutic for a human disease. This model should be useful for gene therapy of human LAD, and may be a prototype for gene therapy for other single gene defects. Barkholt, L. 1 , Bregni, M. 2 , Remberger, M. 1 , Blaise, D. 3 , Peccatori, J. 2 , Massenkeil, G. 4 , Pedrazzoli, P. 5 , Zambelli, A. 6 , Bay, Francois, S. 8 , Martino, R. 9 , Bengala, C. 10 , Brune, M. 11 , Lenhoff, S. 12 , Porcellini, A. 13 , Falda, M. 14 , Siena, S. 5 , Demirer, T. 15 , Niederwieser, D. 16 The immunological graft-versus-tumor (GVT) effect has been reported in various solid cancers after allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated the experience of allogeneic HSCT for renal cell carcinoma (RCC) in Europe.
A SELECTABLE BICISTRONIC RETROVIRAL VECTOR CORRECTS THE MOLECULAR DEFECT IN A CELL LINE DERIVED FROM A PATIENT WITH LEUKOCYTE ADHESION DEFICIENCY

SOLID TUMORS
EUROPEAN EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR METASTATIC RENAL CARCINOMA: ON BEHALF OF THE FRENCH ITAC GROUP AND THE EBMT SOLID TUMOUR WORKING PARTY
Methods and Patients:
We report the data on 124 patients with clear cell RCC, median age 52 years (range 18-68) transplanted in 21 European centers. Various reduced intensity conditionings (RIC) based on fludarabine were used. All patients received allogeneic peripheral blood cells: 106 from an HLAidentical sibling, 5 from mismatched related donor and 13 from matched unrelated donor (MUD). GVHD prophylaxis consisted of cyclosporine A (CyA) alone, or combined with methotrexate or mycophenolate mofetil. All patients with mismatch or MUD received anti-T-lymphocyte immunoglobulin. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 months (range 3-41). Results: All but 3 patients engrafted. The cumulative incidence of grades II-IV acute graft-versus-host disease (GVHD) was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n ϭ 4) or partial (n ϭ 24) responses, median 150 (range 42-600) days posttransplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P Ͻ .001), DLI (HR 3.39, P Ͻ .001), Ͻ3 metastatic sites (HR 2.61, P ϭ .002) and a Karnofsky score Ͼ70 (HR 2.33, P ϭ .03). Patients with chronic GVHD and given DLI (n ϭ 17) had a 2-year survival of 70%. Conclusions: Our data demonstrate that i) RCC patients with less than 3 metastatic locations and a Karnofsky score Ͼ70% may be considered for HSCT, ii) RIC and allogeneic HSCT is feasible in RCC patients with a low non-progression-mortality (16%), iii) a clinically meaningful GVT effect can be generated in these patients, often associated to DLI and chronic GVHD. Chute, J.P., Muramoto, G., Dressman, H., Chao, N.J., Nevins, J. Duke University, Durham, NC. The risk for terrorist-mediated nuclear or radiological attack has been identified as a major threat to the United States in the coming decade. Radiation exposure can cause a spectrum of hematological toxicities, from mild immunosuppression to myeloablation with concordant life threatening complications. Accurate biological dosimetry will be critical, therefore, for caregivers to triage individuals to the appropriate medical management. Currently, biodosimetric tools include lymphocyte depletion kinetic and cytogenetic analysis, both of which require several days for results to be obtained. We propose that high throughput genomic analysis of peripheral blood mononuclear cells (PB MNCs) can sensitively identify patterns of molecular changes which occur following different levels of radiation exposure. In this study, we collected primary PB MNCs from 10 week old C57Bl6 mice at 6 hours following 4 different levels of radiation exposure: normal (nonirradiated), 50 cGy (trivial exposure), 200 cGy (myelosuppressive) and 1000 cGy (lethal). RNA was extracted and used for synthesis of probes for hybridization to spotted arrays. We performed a binary regression analysis to elucidate patterns of gene expression to distinguish between a normal animal and one that had been exposed to various levels of radiation. Distinct gene expression patterns were evident within PB MNCs at each of the 4 exposure levels, demonstrating the feasibility of this approach. We found that the selected metagene pattern for "normal" was able to distinguish normal from 50 cGy, 200 cGy and 1000 cGy exposure with 100% predictive capacity. The predictors selected for 50 cGy, 200 cGy and 1000 cGy were equally powerful at distinguishing these levels of exposure from all others. These data demonstrate the power of this approach to correctly distinguish clinically relevant levels of radiation exposure. In order to validate these molecular predictors generated in mice as profiles of human radiation response, we are currently testing, in a blinded manner, whether these predictors can distinguish different levels of radiation exposure in human PB samples collected from patients who have undergone 200 cGy or 1000 cGy total body irradiation. These validated biomarkers of radiation response can serve as templates for rapid screening tests for radiation exposure and, more broadly, are potential targets for therapeutic intervention.
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